StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Merck (MRK) Shares Rally, Analyst Believes Data Supports Approval of Statercept in PAH
October 10, 2022 11:02 AM
Merck (NYSE: MRK) announced positive top-line results from the pivotal Phase 3 STELLAR trial evaluating the safety and efficacy of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS View
Analyst PT Change
Hot List
Next Articles
Merck (MRK) PT Raised to $103 at Truist Securities on Latest Data
October 10, 2022 9:14 AM
Rivian, Ford Shares Slide Premarket; Toast, Fortinet Rise
October 10, 2022 9:09 AM
Merck Recognized on Fortune’s 2022 Change the World List for Expanding Access to HPV Vaccines
October 10, 2022 8:00 AM
Merck (MRK) Climbs 1.6% After Upgrade, Phase 3 STELLAR Trial of Sotatercept Meets Primary Endpoint
October 10, 2022 7:22 AM
Merck (MRK) Reports Positive Top-line Results from Pivotal Phase 3 STELLAR Trial of Sotatercept
October 10, 2022 6:46 AM
Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)
October 10, 2022 6:45 AM
UPDATE: Guggenheim Upgrades Merck (MRK) to Buy
October 10, 2022 6:42 AM
Merck (MRK) and Ridgeback Biotherapeutics Provide Update on New Studies of LAGEVRIO
October 7, 2022 6:12 AM
Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
October 6, 2022 7:50 PM
